SUBSCRIBE
SUBSCRIBE
News   Drug Development

Regeneron Pharmaceuticals, Inc., Bayer HealthCare Say Eye Drug Meets Mid-stage Goal

February 18, 2010 | 
1 min read

Bookmark and Share

Reuters -- Regeneron Pharmaceuticals and Bayer HealthCare, a U.S. unit of Germany’s Bayer, said their experimental drug to treat retinal swelling brought on by diabetes, met its primary goal in a mid-stage study.

Clinical research Phase II Phase III
Regeneron Pharmaceuticals, Inc.
MORE ON THIS TOPIC
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Infectious disease
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
March 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Entrance to Pfizer's office in Belgium
Breast cancer
Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Dollar banknote cut into pieces on a yellow background
Gene therapy
Roche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy Unit
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac
2D illustration showing scientists' hands editing a DNA strand
Gene editing
Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac